DataMeds AI licenses REBOOT Health AI platform for $2M stock; says it regained Nasdaq equity compliance

Wellgistics Health, Inc.

IP License Agreement dated Oct 13, 2026 with REBOOT Health AI: exclusive US license for GLP-1 weight management B2C use; consideration 666,667 shares valued at $2,000,000.
If share value is below $2,000,000 after 180 days, DataMeds must issue more shares using 10-day VWAP; also paying REBOOT $50,000 toward a minimum $100,000 reconfiguration.
Nasdaq: April 13, 2026 deficiency letter cited $(12,447,801) stockholders' equity at FY2025 vs $2,500,000 minimum under Rule 5550(b)(1); company believes it now exceeds $2.5M after transactions.
Compliance steps: converted ~$1.5M vendor payables to stock (Jul-Oct 2026), issued 636,328 shares for Helomics acquisition, and a Sept 17, 2026 settlement extinguished ~$18.7M debt.
License runs perpetually until last patent expires, terminable for uncured breach after 30-day notice or missed minimum revenue thresholds; REBOOT retains platform IP and source code.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.